This research demonstrated for the first time that ARST acts as a tumor suppressor in GBM by a non-metabolic pathway associated with ALDOA, which may be a potential therapeutic target for glioma diagnoses, therapies, and prognoses. This evidence concerns the gene ALDOA and neoplasm.